Loading patent…
OwnerBoris Skurkovich, Ellen Millstein +1inventors
InventorsBoris Skurkovich, Ellen Millstein, Simon Skurkovich
Estimating the term…
A method for treating renal failure associated with advanced stage renal disease includes administering a soluble cytokine receptor to one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6; or antibodies to one or more of interleukin 6 or interleukin 1 beta. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof. The composition can be included in a kit.
A method for treating a patient suffering from chronic renal failure, associated with elevated levels of one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6, the method comprising administering to the patient a soluble cytokine receptor to the one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6, wherein the soluble cytokine receptor is administered in an amount effective to reduce levels of the one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6.
A method for treating a patient suffering from chronic renal failure, associated with elevated levels of interleukin-6, interleukin 1 beta or both, the method comprising administering to the patient antibodies to interleukin 6, antibodies to interleukin 1 beta, or antibodies to interleukin 6 and antibodies to interleukin 1 beta, wherein the antibodies are administered in an amount effective to reduce levels of interleukin-6, interleukin 1 beta or both.
Dependencies are inferred from the claim text.